메뉴 건너뛰기




Volumn 26, Issue 5, 2015, Pages 998-1005

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Author keywords

Biomarker; Phase I; Refractory solid malignancies; STAT3 inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DRUG METABOLITE; OPB 51602; STAT3 PROTEIN; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

EID: 84929078360     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv026     Document Type: Article
Times cited : (138)

References (12)
  • 1
    • 1042302005 scopus 로고    scopus 로고
    • The STATs of cancer-new molecular targets come of age
    • Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
    • (2004) Nat Rev Cancer , vol.4 , pp. 97-105
    • Yu, H.1    Jove, R.2
  • 2
    • 33845865825 scopus 로고    scopus 로고
    • Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
    • Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
    • (2007) Nat Rev Immunol , vol.7 , pp. 41-51
    • Yu, H.1    Kortylewski, M.2    Pardoll, D.3
  • 3
    • 33645506849 scopus 로고    scopus 로고
    • Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
    • Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006; 66: 3162-3168.
    • (2006) Cancer Res , vol.66 , pp. 3162-3168
    • Alvarez, J.V.1    Greulich, H.2    Sellers, W.R.3    Meyerson, M.4    Frank, D.A.5
  • 4
    • 64849111865 scopus 로고    scopus 로고
    • Targeting STAT3 in cancer: how successful are we?
    • Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009; 18: 45-56.
    • (2009) Expert Opin Investig Drugs , vol.18 , pp. 45-56
    • Yue, P.1    Turkson, J.2
  • 5
    • 84929071293 scopus 로고    scopus 로고
    • Novel inhibitors of signal transducer and activator of transcription 3 (STAT3) show potent activity in cell cultures and tumor xenografts
    • Genini D, Brambilla L, Laurini E, Civenni G. Novel inhibitors of signal transducer and activator of transcription 3 (STAT3) show potent activity in cell cultures and tumor xenografts. Can Res 2014; 74: 953.
    • (2014) Can Res , vol.74 , pp. 953
    • Genini, D.1    Brambilla, L.2    Laurini, E.3    Civenni, G.4
  • 6
    • 0032757213 scopus 로고    scopus 로고
    • Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group
    • Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
    • (1999) Eur J Cancer , vol.35 , pp. 1773-1782
    • Young, H.1    Baum, R.2    Cremerius, U.3
  • 7
    • 59849101586 scopus 로고    scopus 로고
    • Function of mitochondrial Stat3 in cellular respiration
    • Wegrzyn J, Potla R, Chwae YJ et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009; 323: 793-797.
    • (2009) Science , vol.323 , pp. 793-797
    • Wegrzyn, J.1    Potla, R.2    Chwae, Y.J.3
  • 8
    • 79959609376 scopus 로고    scopus 로고
    • Mitochondrial localized STAT3 is involved in NGF induced neurite outgrowth
    • Zhou L, Too HP. Mitochondrial localized STAT3 is involved in NGF induced neurite outgrowth. PLoS ONE 2011; 6: e21680.
    • (2011) PLoS ONE , vol.6
    • Zhou, L.1    Too, H.P.2
  • 9
    • 84864703156 scopus 로고    scopus 로고
    • Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
    • van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519.
    • (2012) N Engl J Med , vol.367 , pp. 508-519
    • van Vollenhoven, R.F.1    Fleischmann, R.2    Cohen, S.3
  • 10
    • 84905726946 scopus 로고    scopus 로고
    • Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
    • Lee HJ, Zhuang G, Cao Y et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014; 26: 207-221.
    • (2014) Cancer Cell , vol.26 , pp. 207-221
    • Lee, H.J.1    Zhuang, G.2    Cao, Y.3
  • 11
    • 84861023172 scopus 로고    scopus 로고
    • Somatic STAT3 mutations in large granular lymphocytic leukemia
    • Koskela HL, Eldfors S, Ellonen P et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-1913.
    • (2012) N Engl J Med , vol.366 , pp. 1905-1913
    • Koskela, H.L.1    Eldfors, S.2    Ellonen, P.3
  • 12
    • 84903816370 scopus 로고    scopus 로고
    • Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    • Bendell JC, Hong DS, Burris HA, III et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 2014; 74: 125-130.
    • (2014) Cancer Chemother Pharmacol , vol.74 , pp. 125-130
    • Bendell, J.C.1    Hong, D.S.2    Burris I.I.I, H.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.